Alloy raises $75M to advance biologics discovery platforms

By The Science Advisory Board staff writers

April 2, 2021 -- Biotechnology ecosystem company Alloy Therapeutics announced it has closed $75 million in series C funding.

The funding round was led by 8VC, Presight Capital, and Peter Thiel, with participation from new investors as well as existing investors Luma Bio-IT, Alexandria Venture Investments, and Ulysses Diversified Holdings.

Alloy Therapeutics democratizes access to tools, technologies, and services related to therapeutic biologics, the company said. The funding will extend Alloy's platforms and services into adjacent biologic modalities and expand Alloy's access to more partners and geographies around the world.

Related to the series C financing, Fabian Hansen of Presight Capital will join Alloy's board of directors. In addition, Alaa Halawa of Mubadala Capital's U.S. Ventures business will join as a board observer.

Since 2017, Alloy has partnered with more than 70 organizations on its ATX-Gx platform for human antibody discovery and formed multiple new biotechnology companies, including Broadwing Bio.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter